Aldehaim M, Mahmood R, Hussain F, Memon A, Al-Hebshi A, Al-Rajhi N, El-Sebaie M, Khalil E, Ahmad M
Mohammed Aldehaim, M.D., Research Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. Tel. No. 00966114647272 Ext 24969. Mobile: 00966506288013 / 001416-822-5559. Email:
Research Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Gulf J Oncolog. 2014 Jan;1(15):32-7.
Anaplastic Thyroid Cancer (ATC) is one of the most lethal malignancies with very short survival and extremely poor treatment outcome. ATC accounts for 2-5% of all thyroid cancers worldwide with an annual incidence of about 2 million.
To review the natural history and treatment outcome of ATC patients treated at King Faisal Specialist Hospital and Research Centre (KFSH and RC) located at Riyadh, Saudi Arabia.
Retrospective review of 120 Saudi cancer patients collected from registry data at KFSH & RC from 1976-2008. Search key words included: thyroid cancer, anaplastic, undifferentiated and not otherwise specified. Search was not restricted to particular age, gender, treatment or tumor size. Demographic information, baseline patient characteristics including date of diagnosis, type of treatment and date of death were obtained from KFSH & RC registry data and Saudi death registry.
A total of 120 cases were identified at our cancer centre from 1976 to 2008. Of these total, 73 were females (60.8%) and 47 were males (39.2%). The average age at diagnosis was 63.34 +/- 12.8 years. Thirty-four patients underwent surgery (28.3%), 52 had a palliative radiation treatment (43.3%) and only 5 had chemotherapy (4.2%). The median survival was 53 days (0-457).
Our review proves that ATC is rapidly fatal cancer and is unresponsive to currently available therapeutic options. More research is needed to understand the tumor biology and novel treatment options.
thyroid cancer, anaplastic, undifferentiated, radiation treatment, chemotherapy, median survival, Riyadh and Saudi Arabia.
间变性甲状腺癌（ATC）是最致命的恶性肿瘤之一，生存期极短，治疗效果极差。ATC占全球所有甲状腺癌的2%-5%，年发病率约为200万。
回顾在沙特阿拉伯利雅得的法赫德国王专科医院及研究中心（KFSH & RC）接受治疗的ATC患者的自然病史和治疗结果。
对1976年至2008年期间从KFSH & RC登记数据中收集的120例沙特癌症患者进行回顾性研究。检索关键词包括：甲状腺癌、间变性、未分化及未另行说明。检索不限于特定年龄、性别、治疗方法或肿瘤大小。人口统计学信息、患者基线特征（包括诊断日期、治疗类型和死亡日期）从KFSH & RC登记数据和沙特死亡登记处获取。
1976年至2008年期间，我们癌症中心共确诊120例病例。其中，女性73例（60.8%），男性47例（39.2%）。诊断时的平均年龄为63.34±12.8岁。34例患者接受了手术（28.3%），52例接受了姑息性放疗（43.3%），只有5例接受了化疗（4.2%）。中位生存期为53天（0-457天）。
我们的研究证明，ATC是一种迅速致命的癌症，对目前可用的治疗方法无反应。需要更多研究来了解肿瘤生物学和新的治疗选择。
甲状腺癌、间变性、未分化、放射治疗、化疗、中位生存期、利雅得和沙特阿拉伯
